Regarding "A process-based review of mouse models of pulmonary hypertension" Editor:
We wish to respond to the review article by Mita Das et al. entitled "A process-based review of mouse models of pulmonary hypertension" (Pulmonary Circulation OctoberDecember 2012:2 [4] ). Genetically modified mouse models have provided curious data for researchers in cancer, obesity, heart disease, diabetes, arthritis, substance abuse, anxiety, aging, and Parkinson's disease; but how cost-effective or translational is this mouse research? Just one gene knockout kit will set you back US $ 38,000. [1] Crowley [2] and Contopoulos-Ioannidis et al. [3] have shown that successful translation to humans for this kind of basic research is exceedingly rare. [4] According to the review article "Transgenic mouse models are a perfect tool for studying the processes involved in pulmonary vascular function and disease, and can be used effectively to test interventions designed against particular molecular pathways and processes involved in disease." Unfortunately, any attempt to extrapolate results between complex systems with different evolutionary trajectories (mice and humans are examples of complex systems, separated by 70 million years) will be limited to conserved processes whose trait or response being studied occurs at the same level of organization or in the same module. [5] Pulmonary vascular function has both intrinsic and extrinsic multifactorial genetic components, which are not amenable to such reductionist study. Genes work in networks and in the context of complex systems, small changes at the gene level can have major consequences for the individual. Thus, it is irrelevant to focus on observed similarities in genetic makeup (including transgenes) between mice and humans, since the details of the differences are in the interactions between conserved genes, not in the genes themselves. [6] We conclude that the use of animals as human models for drug and disease research ignores the very principles upon which modern personalized medicine is based. Therefore, human-based research should become the primary means for obtaining data about human diseases and response to drugs. [7] Andre Menache 1 and Anne Keogh
Author's Reply
We entirely agree that humans are, theoretically, the best system in which to study human disease. To some extent, the problem with mouse modeling is even worse than Drs Menache and Keogh claim: Not only do mice have different responses to pulmonary vascular stress than do humans, but different strains of mice have rather different responses compared to each other, on both a physiologic and molecular level. [1] Moreover, I doubt even the most optimistic mouse modeler believes that any of the dozens of substances that reverse monocrotaline-related pulmonary arterial hypertension (PAH) are likely to be directly relevant to human disease. [2] This is not, however, a reason to abandon mouse modeling. The problem is that there are a great many questions that simply cannot be effectively studied in humans. For instance, the largest expression array study performed directly on lungs from humans with pulmonary hypertension found that of 14,000 genes with detectable levels of expression; 13,889 had significant changes. [3] The signal of etiologic change was overwhelmed with the noise of damage associated with end-stage disease. It is not possible to study initiating events in idiopathic pulmonary hypertension in humans; even with the best registries of not-yet-affected mutation carriers, conversion to disease is so slow that recruitment goals could not practically be met. There are also a great many experiments in gene-gene interaction, especially where these meet Letters to Editor physiologic consequences, which simply cannot be studied in humans.
How, then, are we to make progress, when experiments cannot be done in humans, and we cannot trust the results from mice? The answer is, thoughtfully. As Drs Keogh and Menache point out, genes do not work individually or in linear pathways, but rather in networks. We can use mice to work out the links in these networks, while understanding that the relative strengths of the connections are different in humans and in mice (and likely different from human to human, as well). We can use mice to understand how local and circulating stem cells or transdifferentiation or proliferation of local cells contribute to remodeling, while understanding that the proportions of these cells are likely different in humans. Most of all, we need to understand that the origins of disease in mice are designed to be simple, where in humans they are inevitably multifactorial and complicated by environment and the continued course of disease.
In summary, we entirely agree with Drs Keogh and Menache that use of mouse models is fraught with scientific peril. Our goal in drafting our review was to help the community think more critically about how best to approach this peril. 
Mita

Circulating endothelial progenitor cells in adults with sickle cell disease
Editor:
We appreciated the quality of the project by Anjum et al., [1] concerning circulating endothelial progenitor cells (EPCs) in patients with sickle cell disease. An increasing body of data indicates that intravascular hemolysis contributes to a state of vascular dysfunction in sickle cell disease, especially involving diminished nitric oxide (NO) bioavailability. This vascular dysfunction is detected on venous occlusion plethysmography blood flow physiology studies as a relative blunting of NOinduced vasodilation [2] [3] [4] and this state of NO resistance has also been observed in sickle cell mouse models. [5, 6] This vascular dysfunction may play a role in the development of pulmonary hypertension in sickle cell disease. [7] In our study of 24 adults with sickle cell anemia (SCA), EPC levels trended lower than in 10 healthy AfricanAmerican controls (median 2.50 vs. 8.88 colonies/ well, P = 0.059, Fig. 1A ). This difference might be due to SCA, but also possibly to the study entry criteria for the SCA subjects that selected mainly for patients with high soluble vascular cell adhesion molecule-1, a marker associated with vascular dysfunction.
[8] Low circulating counts of EPCs have correlated in the general population with cardiac disease risk factors, [9] supporting parallels between markers of vascular disease in the general population. Consistent with such a parallel, we found that lower than median EPC number in our SCA subjects is associated with elevated Doppler-estimated pulmonary arterial pressures by tricuspid regurgitant velocity (mean 2.57 vs. 2.38 m/s, P = 0.039, Fig. 1B) . We also find that low EPC number is associated with endothelial dysfunction, detected as a blunted vasodilatory response to acetylcholine infusion into the brachial artery (P = 0.017, Fig. 1C ), but not with infusion of sodium nitroprusside as a control for endothelial-independent vascular function (Fig. 1D ).
We note with caution the risk that statistical significance by Anjum et al., [1] could be an artifact of the multiple comparisons they computed. Similarly, we note caveats with our own results. To measure circulating EPC, we used a fibronectin cell culture assay that was previously accepted. Our own gene expression profiling publication suggests contamination of the EPCs detected in that assay with activated T lymphocytes, clouding accurate quantification by the cell culture EPC assay.
[10] However, the concurrence of EPC results and elevated pulmonary artery pressure from our two research groups using different assay approaches suggests that the findings of both groups are not simply artifacts, and
